Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment (Q42249938)

19 October 2017

Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment (English)

1 reference

19 October 2017

1 reference

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Seto WK

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ivan Fan Ngai Hung

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ching-Lung Lai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

8

Man-Fung Yuen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2

Yuk-Fai Lam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Danny Ka-Ho Wong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Fung-Yu Huang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

1 May 2014

1 reference

Journal of Gastroenterology and Hepatology

19 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

1028-1034

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

Lamivudine for patients with chronic hepatitis B and advanced liver disease

10 June 2020

cites work

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

21 January 2018

1 reference

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.

21 January 2018

1 reference

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance.

21 January 2018

1 reference

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach

21 January 2018

1 reference

Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment".

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

Future prevention and treatment of chronic hepatitis B infection.

21 January 2018

1 reference

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

Acute-on-chronic liver failure in chronic hepatitis B.

21 January 2018

1 reference

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

21 January 2018

1 reference

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

21 January 2018

1 reference

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

21 January 2018

1 reference

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

21 January 2018

1 reference

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

21 January 2018

1 reference

Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment

21 January 2018

1 reference

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

21 January 2018

1 reference

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

21 January 2018

1 reference

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome

21 January 2018

1 reference

Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.12476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24325451%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference